Commit Biologics, a biotech company pioneering complement system activation, has appointed Thomas Montgomery Andresen as Chief Executive Officer (CEO), effective 16 March 2026. Thomas, a biotech ...
Incyte Biosciences UK’s Opzelura (ruxolitinib) cream has been approved for reimbursement for eligible patients with non-segmental vitiligo by the National Institute for Health and Care Excellence ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果